# Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct02788981/  
OnCo record `nct02788981` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mifepristone and Paclitaxel / nab-paclitaxel in Breast cancer, run by University of Chicago, active and no longer recruiting.

## Summary

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT02788981 by University of Chicago, with 29 participants planned, started 2017-03-28 and due to reach its primary completion in 2022-12-21. Interventions recorded: Mifepristone, Placebo, Nab-Paclitaxel. Conditions recorded: Breast Cancer.

Linked to the drug Mifepristone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02788981
- Phase: 2
- Setting: A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
- Sponsor: University of Chicago
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT02788981: https://clinicaltrials.gov/study/NCT02788981

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Mifepristone](https://onco.cc/drugs/mifepristone/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct02788981.json